JP2012533299A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533299A5
JP2012533299A5 JP2012520638A JP2012520638A JP2012533299A5 JP 2012533299 A5 JP2012533299 A5 JP 2012533299A5 JP 2012520638 A JP2012520638 A JP 2012520638A JP 2012520638 A JP2012520638 A JP 2012520638A JP 2012533299 A5 JP2012533299 A5 JP 2012533299A5
Authority
JP
Japan
Prior art keywords
expression vector
promoter
nucleic acid
acid sequence
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012520638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533299A (ja
JP5828838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/036247 external-priority patent/WO2011008348A2/en
Publication of JP2012533299A publication Critical patent/JP2012533299A/ja
Publication of JP2012533299A5 publication Critical patent/JP2012533299A5/ja
Application granted granted Critical
Publication of JP5828838B2 publication Critical patent/JP5828838B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012520638A 2009-07-15 2010-05-26 ヒト免疫不全ウイルス阻害のための二重ベクター Expired - Fee Related JP5828838B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22568709P 2009-07-15 2009-07-15
US61/225,687 2009-07-15
US28759909P 2009-12-17 2009-12-17
US61/287,599 2009-12-17
PCT/US2010/036247 WO2011008348A2 (en) 2009-07-15 2010-05-26 Dual vector for inhibition of human immunodeficiency virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015163281A Division JP6247259B2 (ja) 2009-07-15 2015-08-21 ヒト免疫不全ウイルス阻害のための二重ベクター

Publications (3)

Publication Number Publication Date
JP2012533299A JP2012533299A (ja) 2012-12-27
JP2012533299A5 true JP2012533299A5 (https=) 2013-07-11
JP5828838B2 JP5828838B2 (ja) 2015-12-09

Family

ID=42797105

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012520638A Expired - Fee Related JP5828838B2 (ja) 2009-07-15 2010-05-26 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2015163281A Expired - Fee Related JP6247259B2 (ja) 2009-07-15 2015-08-21 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2017220978A Expired - Fee Related JP6529141B2 (ja) 2009-07-15 2017-11-16 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2019089588A Expired - Fee Related JP6840189B2 (ja) 2009-07-15 2019-05-10 ヒト免疫不全ウイルス阻害のための二重ベクター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015163281A Expired - Fee Related JP6247259B2 (ja) 2009-07-15 2015-08-21 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2017220978A Expired - Fee Related JP6529141B2 (ja) 2009-07-15 2017-11-16 ヒト免疫不全ウイルス阻害のための二重ベクター
JP2019089588A Expired - Fee Related JP6840189B2 (ja) 2009-07-15 2019-05-10 ヒト免疫不全ウイルス阻害のための二重ベクター

Country Status (9)

Country Link
US (3) US20120201794A1 (https=)
EP (4) EP3659435A1 (https=)
JP (4) JP5828838B2 (https=)
AU (1) AU2010274031B2 (https=)
CA (1) CA2767972A1 (https=)
DK (2) DK2949208T3 (https=)
ES (3) ES2546663T3 (https=)
RU (2) RU2562868C2 (https=)
WO (1) WO2011008348A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909195D0 (en) 1989-04-22 1989-09-13 Cambridge Consultants Scoring system
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201012410D0 (en) * 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
US20140127313A1 (en) * 2011-06-29 2014-05-08 Ronilu Development Corporation Prevention and treatment of hiv infection
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CA2954168C (en) * 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2016014837A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
AU2016261864B2 (en) 2015-05-13 2022-05-26 Csl Behring Gene Therapy, Inc. Bio-production of lentiviral vectors
CN108026593A (zh) * 2015-05-18 2018-05-11 卡琳缪恩股份有限公司 区分hiv-1与慢病毒载体的方法
WO2016186708A1 (en) 2015-05-18 2016-11-24 Calimmune, Inc. Gene therapeutic for the treatment of hiv and uses thereof
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hiv予備免疫化および免疫療法
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
DK3402483T3 (da) 2016-01-15 2024-01-02 American Gene Tech Int Inc Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
DK3426777T3 (da) 2016-03-09 2022-04-25 American Gene Tech Int Inc Kombinationsvektorer og fremgangsmåder til behandling af cancer
CN105861559B (zh) * 2016-04-11 2018-05-01 苏州奥特铭医药科技有限公司 一种能直接反应i型干扰素应答的慢病毒载体及其制备方法与应用
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CN106086075B (zh) * 2016-06-23 2019-08-06 福建医科大学 CXCR4RNAi慢病毒载体的构建方法
IL284348B2 (en) 2016-07-08 2025-06-01 American Gene Tech Int Inc Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
WO2018129540A1 (en) * 2017-01-09 2018-07-12 American Gene Technologies International Inc. Hiv immunotherapy with no pre-immunization step
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
CA3064442A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
MX2020004811A (es) * 2017-11-15 2020-10-07 Weird Science Llc Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 17β-水酸化ステロイド脱水素酵素13型(HSD17B13)iRNA組成物およびその使用方法
EA202190267A1 (ru) 2018-07-15 2021-05-17 Инокиан Байофарма, Инк. Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
AU2022212090A1 (en) * 2021-01-28 2023-07-06 Allogene Therapeutics, Inc. Methods for transducing immune cells
RU2769125C1 (ru) * 2021-09-02 2022-03-28 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Генетическая конструкция для экспрессии генов mNG_CD4-CCR5, рекомбинантная плазмида rVSV_mNG_CD4-CCR5 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CCR5, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp41 ВИЧ-1 тропности R5
RU2768032C1 (ru) * 2021-09-02 2022-03-23 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Генетическая конструкция для экспрессии генов mNG_CD4-CXCR4, рекомбинантная плазмида rVSV_mNG_CD4-CXCR4 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CXCR4, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp 41 ВИЧ-1 тропности X4
CA3259099A1 (en) * 2022-06-15 2023-12-21 Cedars-Sinai Medical Center Non-coding RNA agents (BCYRN1 and their derivatives) for treating immune disorders
WO2026039311A1 (en) * 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
RU2324738C2 (ru) * 2006-06-16 2008-05-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ НА ОСНОВЕ ВЕКТОРНОЙ ПЛАЗМИДЫ pEGFP-N1, ПРОДУЦИРУЮЩАЯ siPHK-ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА 1 ТИПА (ЕЕ ВАРИАНТЫ)
CN101841399B (zh) * 2009-03-16 2013-08-07 上海贝尔股份有限公司 多基站协作接收网络中实现同步上行harq进程的方法和装置
ES2455544T5 (es) * 2009-07-24 2017-08-16 Immune Design Corp Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis

Similar Documents

Publication Publication Date Title
JP2012533299A5 (https=)
RU2012105281A (ru) Двойной вектор для подавления вируса иммунодефицита человека
Mohamed et al. Targeting CCR5 as a component of an HIV-1 therapeutic strategy
AU2014296059B2 (en) Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
JP2023071897A (ja) Hiv感染のrnaガイド処置のための方法および組成物
Bobbin et al. RNA interference approaches for treatment of HIV-1 infection
WO2017132112A1 (en) Methods and compositions for rna-guided treatment of hiv infection
US20210032627A1 (en) Gene therapeutic for the treatment of hiv and uses thereof
TW201602349A (zh) 抗hiv幹細胞及其用途
JP2018518196A5 (https=)
Riley et al. Cell-mediated immunity to target the persistent human immunodeficiency virus reservoir
CN115720520A (zh) 用于预防和/或治疗哺乳动物疾病的组合物和方法
Khalid et al. Stem cell therapy and its significance in HIV infection
US20200061117A1 (en) Protective Chimeric Antigen Receptor Stem Cell Gene Therapy for Viral Infection
Lori et al. Gene therapy approaches to HIV infection
AU2017254831B2 (en) Dual vector for inhibition of human immunodeficiency virus
Engel et al. Gene therapy for inborn and acquired immune deficiency disorders
Re et al. Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs
Sasson et al. Site‐specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV‐1?
CN118103076A (zh) 可用于疾病治疗的慢病毒载体
Matamoros Inhibition of CCR5 and CXCR4 prevents HIV infection
Ledger et al. Cell-Delivered Gene Therapy for HIV
JPH1118779A (ja) 新規核酸及びそのエイズ発症抑制剤としての用途
HK1221488B (en) Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
TW200838873A (en) Inhibition of HIV replication and expression of p24 with eIF-5A